Literature DB >> 34249625

Exploring diagnostic performance of T2 mapping in diffuse glioma grading.

Weibin Gu1, Shiyuan Fang2, Xinyi Hou1, Ding Ma1,3, Shaowu Li1,3,4.   

Abstract

BACKGROUND: To evaluate the diagnostic performance of T2 mapping in differentiating WHO grade II glioma from high-grade glioma (HGG).
METHODS: We conducted a single-center, retrospective diagnostic study. Confirmed diffuse glioma (WHO grade II-IV) patients who underwent post-contrast T1-weighted imaging, T2-weighted imaging, and T2 mapping were included. All diagnoses were based on histological and molecular tests. Seventy-five percent of cases were subsampled to generate receiver operating characteristic (ROC) curves and areas under the curve (AUC), while the remaining cases were used to test the accuracy of T2 mapping. Subsampling was repeated four times. Age, T2 relaxation time, and contrast-enhancement status were used to generate a multivariable ROC curve. T2 relaxation time was also used to generate ROC curves to predict the isocitrate dehydrogenase (IDH) status.
RESULTS: A total of 159 patients were included in the study. After four repeats of subsampling, the AUCs of the T2 mapping ROC curve were 0.801 (95% CI: 0.724-0.879), 0.795 (95% CI: 0.714-0.875), 0.803 (95% CI: 0.723-0.884), and 0.801 (95% CI: 0.716-0.886), with an average sensitivity of 0.753 and an average specificity of 0.767. When applied to the remaining 25% of cases, the accuracy was 75%, 93.75%, 82.50%, and 71.74%. The AUC of the multivariable ROC was 0.927 (95% CI: 0.882-0.971). IDH-mutant and IDH-wildtype gliomas have significantly different T2 relaxation times (146.28 and 124.10 ms, respectively; P=0.001), and the AUC of IDH-mutant prediction was 0.687 (95% CI: 0.585-0.789).
CONCLUSIONS: Quantitative T2 mapping differentiated WHO grade II glioma from HGG with moderate sensitivity and specificity. Given the advantages of short acquisition times and the absence of a contrast agent, our study suggests the application of T2 mapping in pre-operative glioma grading is feasible. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  T2 mapping; diffuse glioma; grading; magnetic resonance imaging (MRI); quantitative

Year:  2021        PMID: 34249625      PMCID: PMC8250032          DOI: 10.21037/qims-20-916

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  20 in total

1.  Spatio-temporal TGV denoising for ASL perfusion imaging.

Authors:  Stefan M Spann; Kamil S Kazimierski; Christoph S Aigner; Markus Kraiger; Kristian Bredies; Rudolf Stollberger
Journal:  Neuroimage       Date:  2017-05-27       Impact factor: 6.556

2.  Arterial spin labeling MR imaging for differentiation between high- and low-grade glioma-a meta-analysis.

Authors:  Alberto Falk Delgado; Francesca De Luca; Danielle van Westen; Anna Falk Delgado
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

3.  Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Albert Lai; Phioanh L Nghiemphu; Shadi Lalezari; Taryar Zaw; Kourosh Motevalibashinaeini; Paul S Mischel; Whitney B Pope
Journal:  J Neurooncol       Date:  2011-06-25       Impact factor: 4.130

4.  Accelerated T2 mapping combining parallel MRI and model-based reconstruction: GRAPPATINI.

Authors:  Tom Hilbert; Tilman J Sumpf; Elisabeth Weiland; Jens Frahm; Jean-Philippe Thiran; Reto Meuli; Tobias Kober; Gunnar Krueger
Journal:  J Magn Reson Imaging       Date:  2018-02-15       Impact factor: 4.813

Review 5.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Authors:  Michael Weller; Martin van den Bent; Jörg C Tonn; Roger Stupp; Matthias Preusser; Elizabeth Cohen-Jonathan-Moyal; Roger Henriksson; Emilie Le Rhun; Carmen Balana; Olivier Chinot; Martin Bendszus; Jaap C Reijneveld; Frederick Dhermain; Pim French; Christine Marosi; Colin Watts; Ingela Oberg; Geoffrey Pilkington; Brigitta G Baumert; Martin J B Taphoorn; Monika Hegi; Manfred Westphal; Guido Reifenberger; Riccardo Soffietti; Wolfgang Wick
Journal:  Lancet Oncol       Date:  2017-05-05       Impact factor: 41.316

6.  Comparison of 18F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study.

Authors:  Antoine Verger; Christian P Filss; Philipp Lohmann; Gabriele Stoffels; Michael Sabel; Hans J Wittsack; Elena Rota Kops; Norbert Galldiks; Gereon R Fink; Nadim J Shah; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-22       Impact factor: 9.236

7.  Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema.

Authors:  Joonmi Oh; Soonmee Cha; Ashley H Aiken; Eric T Han; Jason C Crane; Jeffrey A Stainsby; Graham A Wright; William P Dillon; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2005-06       Impact factor: 4.813

Review 8.  Diffuse Infiltrating Oligodendroglioma and Astrocytoma.

Authors:  Martin J van den Bent; Marion Smits; Johan M Kros; Susan M Chang
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

9.  NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

Authors:  Louis Burt Nabors; Jana Portnow; Mario Ammirati; Joachim Baehring; Henry Brem; Nicholas Butowski; Robert A Fenstermaker; Peter Forsyth; Jona Hattangadi-Gluth; Matthias Holdhoff; Steven Howard; Larry Junck; Thomas Kaley; Priya Kumthekar; Jay S Loeffler; Paul L Moots; Maciej M Mrugala; Seema Nagpal; Manjari Pandey; Ian Parney; Katherine Peters; Vinay K Puduvalli; John Ragsdale; Jason Rockhill; Lisa Rogers; Chad Rusthoven; Nicole Shonka; Dennis C Shrieve; Allen K Sills; Lode J Swinnen; Christina Tsien; Stephanie Weiss; Patrick Yung Wen; Nicole Willmarth; Mary Anne Bergman; Anita Engh
Journal:  J Natl Compr Canc Netw       Date:  2017-11       Impact factor: 11.908

Review 10.  2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know.

Authors:  Derek R Johnson; Julie B Guerin; Caterina Giannini; Jonathan M Morris; Lawrence J Eckel; Timothy J Kaufmann
Journal:  Radiographics       Date:  2017-10-13       Impact factor: 5.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.